Shopping Cart
- Remove All
Your shopping cart is currently empty
BH3I-1
BH3I-1 (BHI1) is a Bcl-2 antagonist.
Catalog No. T1493Cas No. 300817-68-9
Select Batch
Purity:98.2%
Contact us for more batch information
BH3I-1
Catalog No. T1493Alias BHI1Cas No. 300817-68-9
BH3I-1 (BHI1) is a Bcl-2 antagonist.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $38 | In Stock | |
| 10 mg | $59 | In Stock | |
| 25 mg | $118 | In Stock | |
| 50 mg | $197 | In Stock | |
| 100 mg | $338 | In Stock | |
| 200 mg | $485 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "BH3I-1"
Indole-3-carbinol
Indole-3-Methanol, I3C, 3-Indolemethanol
T2947700-06-1
Indole-3-carbinol (I3C), a naturally occurring, orally available cleavage product of the glucosinolate glucobrassicanin, inhibits NF-κB and IκBα kinase activation.
- $29
Size
QTY
Navitoclax
Cited
ABT-263
T2101923564-51-6
Navitoclax (ABT-263) is a potent oral Bcl-2 inhibitor that binds to Bcl-xL, Bcl-2, and Bcl-w proteins (Ki<1 nM), demonstrating antitumor activity and inducing apoptosis.
- $41
Size
QTY
CitedVenetoclax Cited
GDC-0199, ABT-199, ABT199, ABT 199
T21191257044-40-8
Venetoclax (ABT-199) is a Bcl-2 inhibitor (Ki<0.01 nM) with potent, selective, and orally active properties. Venetoclax has a 3-order-of-magnitude lower affinity for Bcl-xL and Bcl-W (Kis=48/245 nM). Venetoclax induces autophagy and apoptosis.
- $48
Size
QTY
Cited(S)-(+)-Ibuprofen
Dexibuprofen, (S)-Ibuprofen
T044851146-56-6
(S)-(+)-Ibuprofen (Dexibuprofen) , is a non-steroidal anti-inflammatory drug (NSAID), inhibiting cyclooxygenase (COX).
- $35
Size
QTY
Lisaftoclax
Bcl-2/Bcl-xl inhibitor 1, APG-2575
T104832180923-05-9
Lisaftoclax (Bcl-2/Bcl-xl inhibitor 1) is an oral dual inhibitor of Bcl-2 and Bcl-xl, with IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively. Lisaftoclax is used to treat chronic lymphocytic leukemia (CLL) by inhibiting the action of the BCL-2 protein, which promotes the death of leukemia cells.
- $187
Size
QTY
NSC232003
T122611905453-18-0
NSC232003 is a highly potent and cell-permeable inhibitor of [UHRF1].
- $90
Size
QTY
Gossypol
Pogosin, NSC 56817, BL 193
T6518303-45-7
Gossypol (BL 193) Acetate is a polyphenolic aldehyde that permeates cells and acts as an inhibitor for several dehydrogenase enzymes.
- $35
Size
QTY
Nutlin-3 Cited
Nutlin3
T2158548472-68-0
Nutlin-3 is an MDM2 antagonist that inhibits MDM2-p53 interaction (Ki=90 nM) and activates p53. Nutlin-3 binds preferentially to the p53-binding pocket of MDM2, leading to stabilization of p53 and activation of the p53 pathway. Nutlin-3 has antitumor activity.
- $54
Size
QTY
CitedTriacetylresveratrol
Acetyl-trans-resveratrol
T566842206-94-0
Triacetylresveratrol (Acetyl-trans-resveratrol) has anti-cancer activity,it inhibits the phosphorylation of STAT3 and NFκB, down-regulates Mcl-1, and up-regulates Bim and Puma in pancreatic cancer cells.
- $68
Size
QTY
Diphenyl disulfide
Phenyl disulfide
T37518882-33-7
Diphenyl disulfide (Phenyl disulfide) shows anticancer activity in breast cancer cell lines.Diphenyl disulfide induces and enhances apoptosis in breast cancer cells through Bax protein hydrolysis activation and concomitant autophagy.Diphenyl disulfide inhibits cell proliferation and viability and reduces colony formation in a dose-dependent manner. Diphenyl disulfide can be used to treat breast cancer.
- $30
Size
QTY
NAcM-OPT
T53742089293-61-6
NAcM-OPT is a specific, reversible inhibitor targeting N-Acetyl-UBE2M interaction with DCN1 （IC50: 79 nM).
- $43
Size
QTY
NAE-IN-M22 Cited
NEDD8 inhibitor M22
T8816864420-54-2
NAE-IN-M22 (NEDD8 inhibitor M22) is a selective, potent and reversible inhibitor of NEDD8 activating enzyme (NAE). NAE-IN-M22 inhibits multiple cancer cell lines and induces apoptosis in A549 cells. NAE-IN-M22 also can inhibit tumor growth in vivo.
- $56
Size
QTY
CitedProduct Introduction
Bioactivity
Chemical Properties
| Description | BH3I-1 (BHI1) is a Bcl-2 antagonist. |
| Targets&IC50 | MDM2-p53:5.3 μM(Kd), BH3-BCL XL:2.4 μM(Ki) |
| In vitro | BH3I-1 inhibits Bcl-xL heterodimerization in vitro. It also induces cytochrome c release[1]. BH3I-1, while inhibiting its reported target Bcl-2/Bim and Bcl-xL/Bim, shows significant inhibition of both the p53/hDM2 and p300/Hif-1a interactions[2]. |
| Cell Research | Cells (5×104 cells per well) are seeded into white 96-well plates (Costar) and treated with various concentrations of the compounds for 48 h. For zVAD-FMK protection experiments, cells are preincubated with 100 μM zVAD-FMK for 1 h before the addition of chemicals. Cell viability is determined with an MTS assay. For PI staining experiments, cells are grown in 24-well plates and then incubated with 2 μg ml/L PI. Cell death is determined by FACS analysis.(Only for Reference) |
| Alias | BHI1 |
| Molecular Weight | 400.31 |
| Formula | C15H14BrNO3S2 |
| Cas No. | 300817-68-9 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: 60 mg/mL (149.9 mM) Ethanol: 11 mg/mL (27.5 mM) | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy BH3I-1 | purchase BH3I-1 | BH3I-1 cost | order BH3I-1 | BH3I-1 chemical structure | BH3I-1 in vitro | BH3I-1 formula | BH3I-1 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.